30 likes | 44 Views
CMOAPI has a full range of raw materials of lorcaserin , and has a total quality management system.Also passed GMP and DMF certification. Visit: https://www.cmoapi.com/our-products/lorcaserin/<br>
E N D
What is Lorcaserin powder? Lorcaserin raw powder is the raw material of drug Lorcaserin,is a kind of White to off-white powder,many fat loss products supplier usually buy high purity Lorcaserin raw powder,then make it into finished one. Lorcaserin is a serotonin 2C receptor agonist for oral administration used for chronic weight management. Its chemical name is (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3- benzazepine hydrochloride hemihydrate. The empirical formula is C11H15Cl2N•0.5H2O, and the molecular weight of the hemihydrate form is 241.16 g/mol. Lorcaserin marketed under the brand name Belviq is a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite. As Obesity becomes normal in modern life, Fat loss product- Lorcaserin was producted. Lorcaserin, like Orlistat, got the Approval of FDA in 1999,was used to help adults who are obese or who are overweight and have weight-related medical problems to lose weight and keep from gaining back that weight. Lorcaserin is in a
class of medications called serotonin receptor agonists.Lorcaserin must be used along with a reduced calorie diet and an exercise plan. Reference 1. "Belviq". Trademarkia. 23 June 2011. Archived from the original on 30 June 2012. Retrieved 27 June 2012. 2. Shukla AP, Kumar RB, Aronne LJ (2015). "Lorcaserin Hcl for the treatment of obesity". Expert Opinion on Pharmacotherapy. 16 (16): 2531–8. doi:10.1517/14656566.2015.1096345. PMID 26472579. 3. "Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug". U.S. Food and Drug Administration (FDA). 13 February 2020. Retrieved 18 February 2020. 4. Bray GA, Frühbeck G, Ryan DH, Wilding JP (May 2016). "Management of obesity". Lancet. 387 (10031): 1947–56. doi:10.1016/S0140-6736(16)00271-3. PMID 26868660. https://www.cmoapi.com/ https://www.cmoapi.com/our-products/lorcaserin/ https://www.facebook.com/Cmoapi-114510347044359/ https://www.pinterest.com/cmoapibiotech/boards/ https://sites.google.com/view/cmoapi-lorcaserin-for-sell/